Allogene Therapeutics Inc (NASDAQ:ALLO)
| 3.66 Delayed Data As of Sep 22 |  -0.06 / -1.61%Today’s Change | 3.63 Today|||52-Week Range 12.21 | -41.81% Year-to-Date |
Latest ALLO News | Press Releases
No recent news for Allogene Therapeutics Inc.
Today’s Trading
| Previous close | 3.72 |
| Today’s open | 3.76 |
| Day’s range | 3.64 - 3.81 |
| Volume | 56,180 |
| Average volume (3 months) | 2,356,106 |
| Market cap | $611.8M |
Data as of 3:59pm ET, 09/22/2023
Growth & Valuation
| Earnings growth (last year) | -22.80% |
| Earnings growth (this year) | -1.66% |
| Earnings growth (next 5 years) | +23.70% |
| Revenue growth (last year) | -99.37% |
| P/E ratio | NM |
| Price/Sales | 3,705.33 |
| Price/Book | 0.79 |
Competitors
| ---- | ||
| CDMOAvid Bioservices Inc | +0.10 | +1.05% |
| EDITEditas Medicine Inc | -0.15 | -1.88% |
| RAPTRapt Therapeutics In... | -1.10 | -6.01% |
Data as of 3:59pm ET, 09/22/2023
Financials
| Next reporting date | November 8, 2023 |
| EPS forecast (this quarter) | -$0.56 |
| Annual revenue (last year) | $243.0K |
| Annual profit (last year) | -$332.6M |
| Net profit margin | -136,885.60% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
